Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition

Thanh Tuan Huynh, Yerra Koteswara Rao, Wei Hwa Lee, Hsin An Chen, T. Do Quyen Le, David T W Tzeng, Liang Shun Wang, Alexander T H Wu, Yuh Feng Lin, Yew Min Tzeng, Chi-Tai Yeh

研究成果: 雜誌貢獻文章

20 引文 (Scopus)

摘要

The aberrant activation of Wnt/β-catenin signaling plays an important role in the carcinogenesis and progression of hepatocellular carcinoma (HCC). Therefore, the Wnt/β-catenin signaling molecules are attractive candidates for the development of targeted therapies for this disease. The present study showed that destruxin B (DB) inhibits the proliferation and induces the apoptosis of HCC cells by decreasing the protein expression of anti-apoptotic Bcl-2 and Bcl-xL and increasing the expression of the proapoptotic protein Bax. More importantly, DB also attenuates Wnt-signaling in HCC cells by downregulating β-catenin, Tcf4, and β-catenin/Tcf4 transcriptional activity, which results in the decreased expression of β-catenin target genes, such as cyclin D1, c-myc, and survivin. Furthermore, DB affects the migratory and invasive abilities of Sk-Hep1 cells through the suppression of markers of the epithelial-mesenchymal transition (EMT). A synergistic anti-proliferative and migratory effect was achieved using the combination of DB and sorafenib in Sk-Hep1 cells. In conclusion, DB acts as a novel Wnt/β-catenin inhibitor and reduces the aggressiveness and invasive potential of HCC by altering the cells' EMT status and mobility. DB in combination with sorafenib may be considered for future clinical use for the management of metastatic HCC.
原文英語
頁(從 - 到)552-561
頁數10
期刊Toxicology in Vitro
28
發行號4
DOIs
出版狀態已發佈 - 六月 2014

指紋

Catenins
Wnt Signaling Pathway
Epithelial-Mesenchymal Transition
Cell growth
Hepatocellular Carcinoma
Modulation
Growth
Apoptosis Regulatory Proteins
Cyclin D1
destruxin B
Carcinogenesis
Proteins
Down-Regulation
Genes
Chemical activation
Apoptosis
Molecules

ASJC Scopus subject areas

  • Toxicology
  • Medicine(all)

引用此文

Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition. / Huynh, Thanh Tuan; Rao, Yerra Koteswara; Lee, Wei Hwa; Chen, Hsin An; Le, T. Do Quyen; Tzeng, David T W; Wang, Liang Shun; Wu, Alexander T H; Lin, Yuh Feng; Tzeng, Yew Min; Yeh, Chi-Tai.

於: Toxicology in Vitro, 卷 28, 編號 4, 06.2014, p. 552-561.

研究成果: 雜誌貢獻文章

@article{37b018a6a8704a19a1ca5c635c1307df,
title = "Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition",
abstract = "The aberrant activation of Wnt/β-catenin signaling plays an important role in the carcinogenesis and progression of hepatocellular carcinoma (HCC). Therefore, the Wnt/β-catenin signaling molecules are attractive candidates for the development of targeted therapies for this disease. The present study showed that destruxin B (DB) inhibits the proliferation and induces the apoptosis of HCC cells by decreasing the protein expression of anti-apoptotic Bcl-2 and Bcl-xL and increasing the expression of the proapoptotic protein Bax. More importantly, DB also attenuates Wnt-signaling in HCC cells by downregulating β-catenin, Tcf4, and β-catenin/Tcf4 transcriptional activity, which results in the decreased expression of β-catenin target genes, such as cyclin D1, c-myc, and survivin. Furthermore, DB affects the migratory and invasive abilities of Sk-Hep1 cells through the suppression of markers of the epithelial-mesenchymal transition (EMT). A synergistic anti-proliferative and migratory effect was achieved using the combination of DB and sorafenib in Sk-Hep1 cells. In conclusion, DB acts as a novel Wnt/β-catenin inhibitor and reduces the aggressiveness and invasive potential of HCC by altering the cells' EMT status and mobility. DB in combination with sorafenib may be considered for future clinical use for the management of metastatic HCC.",
keywords = "Destruxin B, EMT, HCC, Metastasis, Sorafenib combination, Wnt/β-catenin",
author = "Huynh, {Thanh Tuan} and Rao, {Yerra Koteswara} and Lee, {Wei Hwa} and Chen, {Hsin An} and Le, {T. Do Quyen} and Tzeng, {David T W} and Wang, {Liang Shun} and Wu, {Alexander T H} and Lin, {Yuh Feng} and Tzeng, {Yew Min} and Chi-Tai Yeh",
year = "2014",
month = "6",
doi = "10.1016/j.tiv.2014.01.002",
language = "English",
volume = "28",
pages = "552--561",
journal = "Toxicology in Vitro",
issn = "0887-2333",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition

AU - Huynh, Thanh Tuan

AU - Rao, Yerra Koteswara

AU - Lee, Wei Hwa

AU - Chen, Hsin An

AU - Le, T. Do Quyen

AU - Tzeng, David T W

AU - Wang, Liang Shun

AU - Wu, Alexander T H

AU - Lin, Yuh Feng

AU - Tzeng, Yew Min

AU - Yeh, Chi-Tai

PY - 2014/6

Y1 - 2014/6

N2 - The aberrant activation of Wnt/β-catenin signaling plays an important role in the carcinogenesis and progression of hepatocellular carcinoma (HCC). Therefore, the Wnt/β-catenin signaling molecules are attractive candidates for the development of targeted therapies for this disease. The present study showed that destruxin B (DB) inhibits the proliferation and induces the apoptosis of HCC cells by decreasing the protein expression of anti-apoptotic Bcl-2 and Bcl-xL and increasing the expression of the proapoptotic protein Bax. More importantly, DB also attenuates Wnt-signaling in HCC cells by downregulating β-catenin, Tcf4, and β-catenin/Tcf4 transcriptional activity, which results in the decreased expression of β-catenin target genes, such as cyclin D1, c-myc, and survivin. Furthermore, DB affects the migratory and invasive abilities of Sk-Hep1 cells through the suppression of markers of the epithelial-mesenchymal transition (EMT). A synergistic anti-proliferative and migratory effect was achieved using the combination of DB and sorafenib in Sk-Hep1 cells. In conclusion, DB acts as a novel Wnt/β-catenin inhibitor and reduces the aggressiveness and invasive potential of HCC by altering the cells' EMT status and mobility. DB in combination with sorafenib may be considered for future clinical use for the management of metastatic HCC.

AB - The aberrant activation of Wnt/β-catenin signaling plays an important role in the carcinogenesis and progression of hepatocellular carcinoma (HCC). Therefore, the Wnt/β-catenin signaling molecules are attractive candidates for the development of targeted therapies for this disease. The present study showed that destruxin B (DB) inhibits the proliferation and induces the apoptosis of HCC cells by decreasing the protein expression of anti-apoptotic Bcl-2 and Bcl-xL and increasing the expression of the proapoptotic protein Bax. More importantly, DB also attenuates Wnt-signaling in HCC cells by downregulating β-catenin, Tcf4, and β-catenin/Tcf4 transcriptional activity, which results in the decreased expression of β-catenin target genes, such as cyclin D1, c-myc, and survivin. Furthermore, DB affects the migratory and invasive abilities of Sk-Hep1 cells through the suppression of markers of the epithelial-mesenchymal transition (EMT). A synergistic anti-proliferative and migratory effect was achieved using the combination of DB and sorafenib in Sk-Hep1 cells. In conclusion, DB acts as a novel Wnt/β-catenin inhibitor and reduces the aggressiveness and invasive potential of HCC by altering the cells' EMT status and mobility. DB in combination with sorafenib may be considered for future clinical use for the management of metastatic HCC.

KW - Destruxin B

KW - EMT

KW - HCC

KW - Metastasis

KW - Sorafenib combination

KW - Wnt/β-catenin

UR - http://www.scopus.com/inward/record.url?scp=84893741977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893741977&partnerID=8YFLogxK

U2 - 10.1016/j.tiv.2014.01.002

DO - 10.1016/j.tiv.2014.01.002

M3 - Article

C2 - 24434019

AN - SCOPUS:84893741977

VL - 28

SP - 552

EP - 561

JO - Toxicology in Vitro

JF - Toxicology in Vitro

SN - 0887-2333

IS - 4

ER -